Where is AbbVie Inc. (ABBV) Headed According to the Street?

Core Viewpoint - AbbVie Inc. is recognized as a strong investment opportunity by hedge funds, with recent rating updates indicating a generally positive outlook despite some adjustments in price targets [1][2]. Group 1: Rating Updates - Guggenheim reaffirmed a Buy rating for AbbVie with a price target of $242, while UBS revised its target down to $230 from $240, maintaining a Neutral rating [1]. - Evercore ISI adjusted its price target to $228 from $232, keeping an Outperform rating, noting that the 2026 guidance appears beatable despite competition [2]. Group 2: Financial Performance - AbbVie reported full-year net revenues of $61.160 billion for fiscal Q4 and full-year 2025, reflecting an 8.6% increase on a reported basis and an 8.5% increase operationally [3]. - The company reported a diluted EPS of $2.36 on a GAAP basis, down 1.3%, and an adjusted diluted EPS of $10.00, down 1.2%, impacted by a $2.76 per share expense related to acquired IPR&D and milestones [3]. Group 3: Company Overview - AbbVie is a research-based pharmaceutical company focused on developing and selling products for chronic diseases across various therapeutic areas including oncology, gastroenterology, and dermatology [4].